Chronic cannabis use alters dACC-striatal glutamatergic balance
Pharmacology Biochemistry and Behavior · 2023
DOI: 10.1016/j.pbb.2023.173544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2023. Verfasst von Chun S Zuo und 1 weiteren Autor:innen. Beteiligte Einrichtung: McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA. Electronic address: chun@mclean.harvard.edu. Hauptthemen laut MEDLINE: Cannabis, Hallucinogens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, University of Minnesota.
Abstract (Originalsprache)
Prefrontal and striatal glutamate plays an important role in modulating striatal dopamine levels and an imbalance in regional glutamate has been identified in several psychiatric conditions. We hypothesized that this imbalance also exists in cannabis use disorder (CUD). We recently quantified the difference in glutamate of dorsal anterior cingulate (dACC) and striatum regions in the frontostriatal pathway using proton MRS at baseline and on verified abstinent days 7 and 21 in chronic users of cannabis (n = 20) in comparison with age- and sex- matched non-using controls (n = 10). In addition, the Barratt Impulsiveness Scale-11 (BIS) was collected as a measure of inhibitory impulse control of the participants. We found that the difference in glutamate concentrations between the dACC and striatum (ΔdACC-strGlu) of the controls was significantly higher than that of cannabis users across the study timeline (F(1,28) = 18.32, p < 0.0005). The group difference was not affected by age, sex, or alcohol/cigarette consumption. On abstinent day 7, ΔdACC-strGlu was significantly correlated with the corresponding ΔdACC-strGABA among the users (r = 0.837, p < 0.00001). On day 21, ΔdACC-strGlu was negatively associated with monthly cannabis use days (Spearman's rho = -0.444, p = 0.05). Self-reported BIS and its subscales were significantly altered among the users compared to the controls across the study timeline (total F(1,28) = 7.0, p = 0.013; non-planning F(1,28) = 16.1, p < 0.0005; motor F(1,28) = 5.9, p = 0.022; cognitive F(1,28) = 6.1, p = 0.019). These data provide preliminary evidence that chronic cannabis use may lead to a dACC-striatal glutamate imbalance in conjunction with poor impulse control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA. Electronic address: chun@mclean.harvard.edu.
- McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA.
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
- University of Minnesota
- National Institutes of Health
Zitieren
APA
Zuo, C. S., & Lukas, S. E. (2023). Chronic cannabis use alters dACC-striatal glutamatergic balance. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2023.173544
Vancouver
Zuo CS, Lukas SE. Chronic cannabis use alters dACC-striatal glutamatergic balance. Pharmacology Biochemistry and Behavior. 2023. doi:10.1016/j.pbb.2023.173544
BibTeX
@article{Zuo2023,
author = {Zuo, Chun S and Lukas, Scott E},
title = {Chronic cannabis use alters dACC-striatal glutamatergic balance},
journal = {Pharmacology Biochemistry and Behavior},
year = {2023},
doi = {10.1016/j.pbb.2023.173544}
}
EUVIMED